Major adverse events were significantly lower in the FUSION BIOLINE group , occurring in @ % , compared with @ % in the standard ePTFE group ( P = @ ) , principally a result of a lower rate of major graft reinterventions through @ months in the FUSION BIOLINE group ( @ % vs @ % ) .